About CD142
This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces, for example, on monocytes. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. Platelets and monocytes have been shown to express this coagulation factor under procoagulatory and proinflammatory stimuli, and a major role in HIV-associated coagulopathy has been described. Platelet-dependent monocyte expression of coagulation factor III has been described to be associated with Coronavirus Disease 2019 (COVID-19) severity and mortality. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Aug 2020]

About Janelia Fluor 646
Janelia Fluor® 646 was developed at the Janelia Campus of the Howard Hughes Medical Institute but is commercialized by other vendors. The Janelia Fluor®s family is unique in that the fluorophores are cell-permeable and are available in photoactivatable forms. These fluorophores were developed for super-resolution microscopy (STED, PALM and STORM) and live-cell microscopy in the HaloTag and SNAP-tag versions. Janelia Fluor® 646 has an excitation peak at 646 nm and an emission peak at 664 nm.